1Reichardt P,Von Mackwltz G,Thuss-Patience PC,et al.M ulticenter phase 11 study of oral capcitabine (Xeloda) in patients with metastatic breast Callcer relapsing after treatment with a taxane-containing therapy[J].Ann Oncol,2003,14:1227-1233.
2Blum JL,Jones SE,Buzdar AU,et al.Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer[J].J Clin Oncol,1999,17(2):485-493.
6Joan D. Webster-Gandya, Chris Howa, K et al.Palmar - plantar erythrodysesthesia (PPE): A fiterature review with commentary on experience in a cancer centre[J].European Journal of Oncology Nursing (2007) 11,238-246
7Jacobi U,Waibler E, Schuhe P, et al. Release of doxorubicin in sweat:first step to induce the palmar-plantar erythrodysesthesia syndrome?[J].The European Society for Medical Oncology,2005, 16(7):1210-1211
8Mary E, Gordinier, Don S, et al.Elevated body mass index does not increase the risk of palmar - plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin[J], Gynecologic Oncology,2006,106:72 - 74
9Lin E, Morris js, Ayers GD.Effect of celecoxib on capecitabine-induced hand-- foot syndrome and antitumor activity[J].Oncology(Williston Park), 2002, 16(12 SupplNo 14):31- 37
10Samer Abushullaih, M.D,Everardo D, et al. Incidence and Severity of Hand-Foot.Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-institution Experience.Cancer Investigation[J].002, 20(1), 3-10
